Pancreas (Fairfax, Va.)最新文献

Outstanding Outcome of Pancreatic Cancer: What Lessons Do We Learn 胰腺癌的突出结果:我们吸取了什么教训

Pancreas (Fairfax, Va.) Pub Date : 2020-02-01 DOI: 10.17140/POJ-4-E012

M. Saif

引用次数: 1

Outstanding Outcome of Pancreatic Cancer: What Lessons Do We Learn. 胰腺癌的突出结果:我们吸取了什么教训?

Pancreas (Fairfax, Va.) Pub Date : 2020-02-01 Epub Date: 2020-02-12

Muhammad W Saif

引用次数: 0

Why HALO 301 Failed and Implications for Treatment of Pancreatic Cancer. HALO 301失败的原因及其对胰腺癌治疗的意义

Pancreas (Fairfax, Va.) Pub Date : 2019-01-01 Epub Date: 2019-12-20 DOI: 10.17140/POJ-3-e010

Nausheen Hakim, Rajvi Patel, Craig Devoe, Muhammad W Saif

{"title":"Why HALO 301 Failed and Implications for Treatment of Pancreatic Cancer.","authors":"Nausheen Hakim, Rajvi Patel, Craig Devoe, Muhammad W Saif","doi":"10.17140/POJ-3-e010","DOIUrl":"https://doi.org/10.17140/POJ-3-e010","url":null,"abstract":"Survival rates for pancreatic cancer (PC) remain dismal. Current standard of care treatment regimens provide transient clinical benefit but eventually chemoresistance develops leading to poor outcomes. PC is a relatively chemoresistant tumor and one of the explanations for this is attributed to desmoplasia that impedes drug delivery. Based on this, stromal modifying agent such as Pegvorhyaluronidase alfa (PEGPH20) was developed and investigated in phase I-III studies. Although phase I-II studies showed promising results in patients with high hyaluronic acid (HA) expressing tumors, the phase III HALO 301 study failed to miss it's primary endpoint and further development of PEHPH20 is halted. This failure implies that targeting desmoplasia alone is not sufficient and other intrinsic factors such as lack of significant neoantigens, low tumor mutational burden, and epithelial to mesenchymal transition may be at play. It is also important to consider that although the tumor stroma may be a physical barrier hampering drug delivery, it may also have protective effects in restraining tumor growth and progression. Further studies in molecular biology to better characterize the complex interaction between the microenvironment and cancer cells are warranted.","PeriodicalId":20001,"journal":{"name":"Pancreas (Fairfax, Va.)","volume":"3 1","pages":"e1-e4"},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7003617/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37618991","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 62

The Evolving Field of Stereotactic Body Radiation Therapy in Pancreatic Cancer. 胰腺癌立体定向放射治疗领域的发展。

Pancreas (Fairfax, Va.) Pub Date : 2019-01-01 Epub Date: 2019-11-06 DOI: 10.17140/POJ-3-110

Maged Ghaly, Emile Gogineni, Muhammad W Saif

引用次数: 13

PARP Inhibitors in Pancreatic Cancer: From Phase I to Plenary Session. PARP抑制剂在胰腺癌中的应用:从I期到全体会议

Pancreas (Fairfax, Va.) Pub Date : 2019-01-01 Epub Date: 2019-12-20 DOI: 10.17140/POJ-3-e011

Rajvi Patel, Daniel Fein, Carolina B Ramirez, Kevin Do, Muhammad W Saif

{"title":"PARP Inhibitors in Pancreatic Cancer: From Phase I to Plenary Session.","authors":"Rajvi Patel, Daniel Fein, Carolina B Ramirez, Kevin Do, Muhammad W Saif","doi":"10.17140/POJ-3-e011","DOIUrl":"https://doi.org/10.17140/POJ-3-e011","url":null,"abstract":"Survival rates for pancreatic cancer remain dismal. Current standard of care treatment regimens provide transient clinical benefit but eventually chemoresistance develops. Tumors deficient in deoxyribonucleic acid (DNA) damage repair mechanisms such as BRCA mutants show better responses to platinum based agents, however, such tumors can utilize the poly(adenosine diphosphate [ADP]-ribose) polymerase (PARP) pathway as a salvage mechanism. Therefore, inhibition of PARP pathway could lead to tumor destruction and synthetic lethality in presence of BRCA mutation. Various PARP inhibitors have been approved for treatment of patients with germline or somatic BRCA mutant breast and ovarian cancer. This provides basis of using PARP inhibitors in patients with pancreatic cancer that harbor BRCA mutation. A recent phase III Pancreas Cancer Olaparib Ongoing (POLO) study showed impressive results with near doubling of progression free survival compared to placebo (7.4 vs 3.8 months). These results highlight the importance of germline testing for all patients with pancreatic cancer and inclusion of additional deficiencies in homologous recombination repair (ATM and PALB2) including BRCA variants of uncertain significance should be further explored.","PeriodicalId":20001,"journal":{"name":"Pancreas (Fairfax, Va.)","volume":"3 1","pages":"e5-e8"},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7003614/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37620188","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 13